Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer

被引：2
作者：
Roy, Arya Mariam [1 ]
George, Saby [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Dept Med Oncol, Buffalo, NY 14203 USA
来源：
IMMUNOTHERAPY | 2023年 / 15卷 / 06期
关键词：
CTLA-4; immune checkpoint inhibitors; immune-related toxicities; immunosuppressants; immunotherapy; kidney cancer; PD-L1; PD-1; renal cell carcinoma;
D O I：
10.2217/imt-2023-0010
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Plain language summary: Targeted immunotherapy refers to a new class of drugs that boost the body's immune system to fight against cancer. Studies have shown that immunotherapy increases the survival of kidney cancer patients, but it has certain side effects that can affect any organ in the body, including the heart, lungs, skin, bowel and thyroid. Most side effects can be managed with drugs that can suppress the immune system, such as steroids; however, some side effects can be fatal if not diagnosed in a timely manner. It is vital to have a proper understanding of the side effects of immunotherapy drugs when making decisions about treatment for kidney cancer.
引用
收藏
页码：397 / 400
页数：4
相关论文
共 16 条
  • [1] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. ESMO OPEN, 2020, 5 (06)
  • [2] Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
    Choi, Juwhan
    Lee, Sung Yong
    [J]. IMMUNE NETWORK, 2020, 20 (01)
  • [3] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
    Choueiri, T. K.
    Tomczak, P.
    Park, S. H.
    Venugopal, B.
    Ferguson, T.
    Chang, Y. -H.
    Hajek, J.
    Symeonides, S. N.
    Lee, J. L.
    Sarwar, N.
    Thiery-Vuillemin, A.
    Gross-Goupil, M.
    Mahave, M.
    Haas, N. B.
    Sawrycki, P.
    Gurney, H.
    Chevreau, C.
    Melichar, B.
    Kopyltsov, E.
    Alva, A.
    Burke, J. M.
    Doshi, G.
    Topart, D.
    Oudard, S.
    Hammers, H.
    Kitamura, H.
    Bedke, J.
    Perini, R. F.
    Zhang, P.
    Imai, K.
    Willemann-Rogerio, J.
    Quinn, D. I.
    Powles, T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) : 683 - 694
  • [4] Systemic Therapy for Metastatic Renal-Cell Carcinoma
    Choueiri, Toni K.
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) : 354 - 366
  • [5] Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
    Khoja, L.
    Day, D.
    Chen, T. Wei-Wu
    Siu, L. L.
    Hansen, A. R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (10) : 2377 - 2385
  • [6] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. Aren
    Melichar, B.
    Choueiri, T. K.
    Plimack, Elizabeth R.
    Barthelemy, P.
    Porta, C.
    George, S.
    Powles, T.
    Donskov, F.
    Neiman, V.
    Kollmannsberger, C. K.
    Salman, P.
    Gurney, H.
    Hawkins, R.
    Ravaud, A.
    Grimm, M. -O.
    Bracarda, S.
    Barrios, C. H.
    Tomita, Y.
    Castellano, D.
    Rini, B. I.
    Chen, A. C.
    Mekan, S.
    McHenry, M. B.
    Wind-Rotolo, M.
    Doan, J.
    Sharma, P.
    Hammers, H. J.
    Escudier, B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) : 1277 - 1290
  • [7] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Escudier, B.
    McDermott, D. F.
    George, S.
    Hammers, H. J.
    Srinivas, S.
    Tykodi, S. S.
    Sosman, J. A.
    Procopio, G.
    Plimack, E. R.
    Castellano, D.
    Choueiri, T. K.
    Gurney, H.
    Donskov, F.
    Bono, P.
    Wagstaff, J.
    Gauler, T. C.
    Ueda, T.
    Tomita, Y.
    Schutz, F. A.
    Kollmannsberger, C.
    Larkin, J.
    Ravaud, A.
    Simon, J. S.
    Xu, L-A
    Waxman, I. M.
    Sharma, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) : 1803 - 1813
  • [8] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) : 1289 - 1300
  • [9] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial
    Motzer, Robert J.
    Powles, Thomas
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria T.
    Shah, Amishi Y.
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher M.
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Choueiri, Toni K.
    [J]. LANCET ONCOLOGY, 2022, 23 (07) : 888 - 898
  • [10] Ornstein MC, 2017, KIDNEY CANCER, V1, P133, DOI 10.3233/KCA-170017
12